Lang David M
Department of Allergy/Immunology, Cleveland Clinic, Respiratory Institute, Cleveland, Ohio.
Allergy Asthma Proc. 2014 Jan-Feb;35(1):10-6. doi: 10.2500/aap.2014.35.3722.
Chronic urticaria/angioedema (CUA) continues to be a vexing condition for both patients and health care providers. Despite progress made in recent years to improve our understanding of the pathogenesis of CUA and its treatment, many patients continue to experience ongoing symptoms and impaired quality of life. In the overwhelming majority of cases, a definite etiology is not identified. Laboratory testing may be justified based on its "reassurance value"; however, extensive routine testing is not favorable from a cost-benefit standpoint and does not lead to improved patient care outcomes. The target for effective management is to control CUA with a combination of avoidance measures, lifestyle changes, and regular administration of medication. A step-care approach to pharmacologic management that is favorable from the standpoint of balancing the potential for benefit with the potential for harm can lead to substantial improvement in quality of life. This article will focus on achieving improved outcomes for patients with CUA based on evidence-directed recommendations for diagnosis and management.
慢性荨麻疹/血管性水肿(CUA)对于患者和医疗服务提供者而言仍是一个棘手的病症。尽管近年来在增进对CUA发病机制及其治疗的理解方面取得了进展,但许多患者仍持续出现症状且生活质量受损。在绝大多数情况下,无法确定明确的病因。实验室检测基于其“安慰价值”可能是合理的;然而,从成本效益的角度来看,广泛的常规检测并不有利,也不会带来更好的患者护理结果。有效管理的目标是通过避免措施、生活方式改变和定期用药相结合来控制CUA。从平衡获益潜力与潜在危害的角度来看,一种有利于药物管理的逐步护理方法可显著改善生活质量。本文将基于针对诊断和管理的循证建议,着重探讨如何为CUA患者实现更好的治疗效果。